所有图片(1)

文件

1457301

USP

萘普生

Name: 萘普生
Brand: USP

United States Pharmacopeia (USP) Reference Standard

登录查看公司和协议定价

所有图片(1)

别名:

(S)-(+)-2-(6-甲氧基-2-萘基)丙酸

线性分子式:

CH₃OC₁₀H₆CH(CH₃)CO₂H

CAS号:

22204-53-1

分子量:

230.26

Beilstein:

3591068

MDL编号:

MFCD00010500

PubChem化学物质编号:

329750529

NACRES:

NA.24

等级

pharmaceutical primary standard

API family

naproxen

manufacturer/tradename

USP

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

152-154 °C (lit.)

application(s)

pharmaceutical (small molecule)

格式

neat

SMILES string

COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O

InChI

1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1

InChI key

CMWTZPSULFXXJA-VIFPVBQESA-N

Gene Information

human ... PTGS1(5742) , PTGS2(5743)

正在寻找类似产品? Visit 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Naproxen USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

生化/生理作用

非选择性环加氧酶(COX-1 和 COX-2)抑制剂。

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

其他说明

Sales restrictions may apply.

PHR2527

PHR2526

6-甲氧基-2-萘酚, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2520

Naproxen Impurity B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2519

Naproxen Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2518

(R)-(-)-6-甲氧基-α-甲基-2-萘乙酸, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2523

PHR2530

rac-Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2517

PHR2521

萘普生杂质A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2522

萘普生杂质I, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2528

萘普生杂质F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2529

萘普生杂质E, Pharmaceutical Secondary Standard; Certified Reference Material

象形图

GHS07,GHS08,GHS09

警示用语：

Warning

危险声明

H302 - H315 - H319 - H335 - H361fd - H411

预防措施声明

P202 - P273 - P301 + P312 - P302 + P352 - P305 + P351 + P338 - P308 + P313

危险分类

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 3

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

如何查找产品货号

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503

货号

-

25G

包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务寻求帮助

如何查找COA批号

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。
如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。
如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.

Marta L Capone et al.

Journal of the American College of Cardiology, 45(8), 1295-1301 (2005-04-20)

We investigated the occurrence of pharmacodynamic interaction between low-dose aspirin and naproxen. The uncertainty of cardioprotection by naproxen has encouraged its combination with aspirin in patients with arthritis and cardiovascular disease. The incubation of washed platelets with naproxen for 5

Single dose oral naproxen and naproxen sodium for acute postoperative pain in adults.

Christopher Derry et al.

The Cochrane database of systematic reviews, (1)(1), CD004234-CD004234 (2009-01-23)

Naproxen, a non-steroidal anti-inflammatory drug, is used to treat various painful conditions including postoperative pain, and is often administered as the sodium salt to improve its solubility. This review updates a 2004 Cochrane review showing that naproxen sodium 550 mg

Renal papillary necrosis induced by naproxen.

Larisa Kovacevic et al.

Pediatric nephrology (Berlin, Germany), 18(8), 826-829 (2003-05-30)

A 17-year-old healthy girl was admitted to our hospital with diffuse abdominal pain and decreased oral intake of about 11 days duration. About a week prior to admission, she had taken naproxen, 250 mg four times a day for 4

Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine.

Chuthamanee C Suthisisang et al.

Headache, 50(5), 808-818 (2010-03-20)

To assess the efficacy and safety of naproxen sodium in the treatment of acute migraine attacks. Non-steroidal anti-inflammatory drugs including naproxen sodium have been used in treating migraine attack. A number of clinical trials of naproxen sodium in migraine have

Model-based analysis of thromboxane B₂ and prostaglandin E₂ as biomarkers in the safety evaluation of naproxen.

Tarjinder Sahota et al.

Toxicology and applied pharmacology, 278(3), 209-219 (2014-03-29)

The assessment of safety in traditional toxicology protocols relies on evidence arising from observed adverse events (AEs) in animals and on establishing their correlation with different measures of drug exposure (e.g., Cmax and AUC). Such correlations, however, ignore the role

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件

萘普生